Ex Vivo Modelling of Therapy Efficacy for Rare Krukenberg Tumors – A Report of Two Cases
Purpose and Significance of Study: This is the first report of ex vivo study and clinical use of drug efficacy testing in Krukenberg tumors. The study analysed Krukenberg tumor cells from two patients as the prognoses in such cases are generally poor. Tumor cells from both patients showed systematic sensitivity toward topoisomerase inhibition, epigenetic modulators, statins and alkaloid tubulin inhibitors. Ascites-derived immune cells displayed selective sensitivity to a number of targeted agents, including VEGFR inhibitor sunitinib. It warrants further investigation.
Fit with Scope of Journal: The manuscript is of very high interest for the journal Clinical Oncology and Research.
The Discussion and Conclusion details the cause of poor prognosis in Krukenberg tumors, and adequately explains the novelty of the study and implications of the findings, including with respect to cancer treatment in general.
o The manuscript contains a few errors (already corrected in the galley proof) listed below –
· Some words were misspelled, e.g., “Krukenberg” throughout the text, “cytometry” in the 10th sentence of the Abstract, “Pitavastatin” in the 3rd sentence of the last paragraph of “Ex vivo drug efficacy screening” in the Results, and so on.
· In the 2nd and 6th sentences of Tumor tissue derived primary cell cultures, “RMPI” must be replaced with “RPMI”.
· In the 5th sentence of Tumor tissue derived primary cell cultures, “where” must be replaced with “were”.
Juha K. Rantala
Misvik Biology Ltd, Turku, Finland
Received: Thu 04, Jun 2020
Accepted: Mon 22, Jun 2020
Published: Wed 01, Jul 2020
© 2021 Juha K. Rantala. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.